CRKN Stock Cash Flow Statements

Crown Electrokinetics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Crown Electrokinetics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30	2022-06-30	2022-03-31	2021-03-31	2020-12-31	2020-09-30	2020-06-30

cash flows from operating activities
net income	-4,612,000	-9,306,000	-2,859,000	-14,519,000	-2,300,000	-3,116,000	-4,477,000	-4,570,000	-20,673,217	-3,853,396	-5,766,482	-10,462,030
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	274,000	268,000	133,000	132,000	181,000	480,000	1,448,000	1,083,000	3,463,003	1,613,339	970,432	8,079,223
depreciation and amortization	212,000	191,000	170,000	190,000	182,000	126,000	127,000	107,000	46,128	21,428	20,584	14,697
loss on extinguishment of warrant liability		0	0	0	504,000
change in fair value of warrant liability	23,000	-34,000	-2,688,000	-2,130,000	-5,606,000				1,023,188	598,899	861,365	-122,909
gain on issuance of convertible note		0			-64,000
amortization of debt discount					374,000				457,671	266,361	937,786	1,051,698
change in fair value of notes		0	40,000	6,883,000	117,000
amortization of deferred debt issuance costs	944,000	2,541,000	2,751,000	2,414,000	1,635,000
amortization of right-of-use assets	168,000
other incomes		161,000	-808,000	69,000	1,206,000
changes in operating assets and liabilities:
prepaid and other assets	-111,000	-75,000	150,000	147,000	-161,000	389,000	90,000	-87,000
accounts receivable	-693,000
note receivables	-576,000
deferred revenue	1,260,000
accounts payable	797,000	521,000	-154,000	761,000	125,000	-3,000
accrued expenses	-228,000	1,015,000	167,000	178,000	-920,000	17,000	26,000	-208,000	-145,417	113,578	-332,560	-189,905
lease liabilities	-171,000
warranty customer liability	36,000
net cash from operating activities	-2,677,000	-4,351,000	-3,421,000	-3,660,000	-4,728,000	-2,106,000	-2,391,000	-3,552,000	-2,978,970	-811,181	-1,507,576	-1,286,656
capex	0	0	0	0	0	0	0	0	0	0	0	0
free cash flows	-2,677,000	-4,351,000	-3,421,000	-3,660,000	-4,728,000	-2,106,000	-2,391,000	-3,552,000	-2,978,970	-811,181	-1,507,576	-1,286,656
cash flows from investing activities
cash paid for acquisition of amerigen 7		0	-1,000	1,000	-645,000
purchase of equipment	-63,000	-1,089,000	-377,000	-272,000	-435,000	-20,000	-200,000	-58,000	-76,893	-52,913
net cash from investing activities	-63,000	-1,089,000	-378,000	-271,000	-1,080,000	-20,000	-254,000	-65,000	-1,526,893	-77,913
cash flows from financing activities
proceeds from the exercise of warrants		0	1,000	-1,000	2,062,000
proceeds from the issuance of common stock and warrants, net of fees
proceeds from the issuance of common stock / at-the-market offering, net of offering costs	588,000
proceeds from issuance of notes in connection with line of credit
proceeds from issuance of january promissory notes, net of fees paid				387,000	970,000
repayment of notes payable	-8,000	0	-351,000	-1,983,000	-14,000				0	0
proceeds from the issuance of common stock in connection with equity line of credit, net of offering costs	1,391,000	0
net cash from financing activities	1,971,000	4,441,000	5,819,000	1,829,000	7,125,000	1,484,000			19,767,178	323,779	1,545,700	1,830,200
net increase / decrease in cash	-769,000	-997,000	2,020,000	-2,102,000	1,317,000
cash — beginning of period	1,059,000	0	0	0	821,000	0	0	6,130,000		0	0	48,307
cash — end of period	290,000	-997,000	2,020,000	-2,102,000	2,138,000	-642,000	-1,529,000	2,513,000		-565,315	9,073	591,851
supplemental disclosure of non-cash investing and financing activities:
issuance of series e preferred stock in connection with line of credit		0
issuance of common stock in connection with conversion of notes		-516,000	2,165,000	0	516,000					0	2,342,162	2,151,461
commitment to issue shares of common stock in connection with march waiver agreement					298,000
deemed dividend for repricing of series d preferred stock				0	6,000
unpaid equipment included in accounts payable			-69,000	-64,000	156,000	374,000	108,000	4,000
supplemental cash flow information
cash paid for interest		5,000	1,000	0	8,000	0	0	3,000	2,448	4,061	181	55,959
series a preferred stock	3,146,000					0	0	188,311,000
series b preferred stock	33,883,000					0	0	2,019,038,000
series c preferred stock	9,346,000					0	0	560,757,000
series d preferred stock
series e preferred stock
convertible notes										-5,536,997	-2,342,163	8,417,824
series f preferred stock	501,579,000
series f-1 preferred stock	72,631,000
series f-2 preferred stock	124,946,000
warrants to purchase common stock	2,470,078,000					1,176,602,000	0	4,725,177,000		-4,273,483	795,800	5,764,356
warrants to purchase series e preferred stock	750,000,000
options to purchase common stock	632,779,000					767,500,000	-1,496,113,000	10,567,099,000		-6,066,603	2,433,932	14,050,167
unvested restricted stock units	1,124,527,000					370,833,000	-1,745,276,000	2,261,905,000
commitment shares	212,890,000
total	5,935,805,000
change in fair value of liability
loss on extinguishment of debt		0	0						13,804,849	255,046	179,400	18,200
amortization of right of use assets				912,000	133,000	126,000	121,000	118,000
impairment of goodwill
intangible asset impairment
loss on lease termination
loss on disposal of equipment		-236,000	145,000			0	0	52,000
lease liability				-967,000	-134,000	-125,000	-128,000	-15,000
purchase of patents						0	-54,000	-7,000
proceeds from the issuance of common stock / at-the-market offering		4,441,000	1,759,000	0	2,198,000	672,000
proceeds from the issuance of notes in connection with line of credit		0	0	350,000	2,000,000
offering costs for the issuance of common stock / at-the-market offering		0	-79,000	0	-91,000	-24,000
proceeds from issuance of senior secured convertible notes and common stock warrants									0	626,000	0	2,050,000
proceeds from issuance of series d preferred stock and warrants, net of fees
proceeds from issuance of series f-1 preferred stock		0	0
proceeds from issuance of series f-2 preferred stock		0	0
issuance of common stock in connection with equity line of credit		0
issuance of series f preferred stock in connection with exchange of series d preferred stock		0	0
issuance of common stock in connection with senior secured notes settlement		0
issuance of common stock warrants in connection with sloc						0	0	223,000
commitment to issue shares of common stock connection with demand notes
conversion of senior secured notes into series f preferred stock
issuance of common stock warrants in connection with consideration payable
acquisitions of property and equipment included in liabilities
right-of-use assets obtained in exchange for operating lease liabilities
reduction of right of use asset and operating lease liability due to early lease termination
●
change in fair value of derivative liability
proceeds from a deposit for series d preferred stock
proceeds from issuance of senior secured notes, net of fees paid
conversion of senior secured notes into series f preferred stock in connection with exchange agreements
commitment to issue shares of common stock in connection with demand notes			0
issuance of series e preferred stock in connection with loc				5,593,000	4,350,000
issuance of common stock to consultants									3,326	20,000	0	282,109
gain on forgiveness of ppp loan
proceeds from exercise of stock options
net decrease in cash
cash — beginning of year
cash — end of year
numerator
cumulative dividends on series d preferred stock
numerator for basic and diluted net income per share
denominator
weighted-average common shares outstanding
less: weighted-average shares subject to repurchase
denominator for basic and diluted net income per share
shares used to compute pro forma net income per share, basic and diluted
net income per share
basic and diluted
loss on exchange of notes payable for common stock and warrants									5,836	0
accrued interest									71,247	70,459	151,837	126,556
proceeds from the exercise of common stock warrants
proceeds from ppp loan									233,300	0	0	205,200
repayment of related party non interest bearing advance
net increase increase in cash						-642,000
issuance of common stock and preferred stock in connection with conversion of notes
repurchase beneficial conversion feature in connection with conversion of notes payable
reclassification of warrant liabilities									3,565,603
issuance of common stock warrants in connection with note exchange agreements
proceeds from the issuance of common stock, net of fees										0
proceeds from a deposit for the series d preferred stock
cash paid income taxes
unvested restricted stock awards											-749,997	3,000,012
(gain) loss on extinguishment of debt
account payable								-32,000	-922,471	231,601	600	-112,134
net increase in cash								-3,617,000			9,073	543,544
non-cash expenses for placement agent									0	0
proceeds from the exercise of stock options
repayment of senior secured promissory note									0	0	0	-200,000
common stock repurchased and subsequently canceled									0	-225,000	0	-225,000
unpaid research and development license included in accounts payable										0	-25,000	100,000
beneficial conversion feature in connection with notes payable									0	0	0	618,657
issuance of common stock in connection with notes payable									0	203,500	179,400	750,750
issuance of common stock in satisfaction of accounts payable									0	0	0	121,835
issuance of common stock and warrants
deferred offering costs
bad debt expense
proceeds from related party non-interest bearing advance									0
proceed from the exercise of common stock warrants
proceeds from notes payable
repayment of related party non-interest bearing advance									-25,000
unpaid deferred offering costs
repurchased beneficial conversion feature in connection with conversion of notes payable
canceled restricted stock awards									6
issuance of common stock warrants in connection with notes payable
exercise of stock options
issuance of common stock and warrants in connection with cancellation of consulting agreement
chang in fair value of derivative liability
prepaid and other current assets										-109,725	-84,400	5,392
purchase of research and development license
payment of financing costs
change in cash overdraft
exercise of common stock warrants										-19	0	29
issuance of common stock warrants
proceeds from related party
loss on conversion of notes												22,447
due to related parties

We provide you with 20 years of cash flow statements for Crown Electrokinetics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Crown Electrokinetics stock. Explore the full financial landscape of Crown Electrokinetics stock with our expertly curated income statements.

The information provided in this report about Crown Electrokinetics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.